Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital (Zhuhai hospital affiliated with Jinan University), Zhuhai, Guangdong, 519000, China.
Department of Urology, Zhuhai Interventional Medical Center, Zhuhai Precision Medical Center, Zhuhai People's Hospital (Zhuhai hospital affiliated with Jinan University), Zhuhai, Guangdong, 519000, China.
Int J Med Sci. 2020 Oct 18;17(18):2926-2940. doi: 10.7150/ijms.51145. eCollection 2020.
Illustrating the pathogenesis of hepatocellular carcinoma (HCC) pathogenesis as well as identifying specific biomarkers are of great significance. The original CEL files were obtain from Gene Expression Omnibus, then affymetrix package was used to preprocess the CEL files, the function of DEGs were investigated by multiple bioinformatics approach. Finally, typical HCC cell lines and tissue samples were using to validate the role of CDC6 in vitro. Bioinformatics software was used to predict potential microRNA of CDC6. Luciferase assay was used to verify the interactions between CDC6 and microRNA. A total of 445 DEGs were identified in HCC tissues based on two GEO datasets. GSEA results showed that the significant enriched gene sets were only associated with cell cycle signaling pathway. In the co-expression analysis, there were 370 hub genes from the blue modules were screened. We integrated DEGs, hub genes, TCGA cohort and GSEA analyses to further obtain 10 upregulated genes for validation. These genes were overexpressed in HCC tissues and negatively associated with overall and disease-free survival in HCC patients and related to immune cell infiltration in HCC microenvironments. Finally, Cell Division Cycle 6 (CDC6) was highlighted as one of the most probable genes among the 10 candidates participating in cancer process. The expression of CDC6 either in public datasets and HCC tissues sample were commonly high than the non-cancerous counterpart. Furthermore, we recognized that miR-215-5p, could directly bind to the 3'UTR of CDC6. In addition, CDC6 promoted proliferation via regulation of G1 phase checkpoint and was negative regulated by miR-215-5p to involve in the proliferation of HCC. Our study suggested that CDC6 served as a potential therapeutic target for HCC.
阐明肝细胞癌 (HCC) 的发病机制以及鉴定特异性生物标志物具有重要意义。从基因表达综合数据库中获取原始 CEL 文件,然后使用 affymetrix 包对 CEL 文件进行预处理,通过多种生物信息学方法研究差异表达基因的功能。最后,使用典型的 HCC 细胞系和组织样本在体外验证 CDC6 的作用。使用生物信息学软件预测 CDC6 的潜在 microRNA。使用荧光素酶 assay 验证 CDC6 与 microRNA 之间的相互作用。基于两个 GEO 数据集,在 HCC 组织中鉴定出 445 个差异表达基因。GSEA 结果表明,显著富集的基因集仅与细胞周期信号通路相关。在共表达分析中,从蓝色模块中筛选出 370 个枢纽基因。我们整合差异表达基因、枢纽基因、TCGA 队列和 GSEA 分析,进一步获得 10 个上调基因进行验证。这些基因在 HCC 组织中过表达,与 HCC 患者的总生存期和无病生存期呈负相关,并且与 HCC 微环境中的免疫细胞浸润相关。最后,细胞分裂周期 6 (CDC6) 被突出为 10 个候选基因之一,可能参与癌症进程。CDC6 的表达在公共数据集和 HCC 组织样本中均高于非癌组织。此外,我们发现 miR-215-5p 可以直接与 CDC6 的 3'UTR 结合。此外,CDC6 通过调节 G1 期检查点促进增殖,并且受 miR-215-5p 的负调控,参与 HCC 的增殖。我们的研究表明,CDC6 可能成为 HCC 的潜在治疗靶点。